MEDX Xelerator 05.20.20
MEDX Xelerator, an Israeli medtech incubator, announced that Inbal Landsberg has been appointed as its new chief business officer. Landsberg will manage MEDX Xelerator’s relationships with current and potential international partners including healthcare organizations, technology developers and integrators, patient groups and more.
“Inbal is a valuable and well-rounded addition to the MEDX Xelerator team given her strong background in fundraising, intellectual property know-how, as well as vast experience covering due diligence of investment opportunities and demonstrated ability to perform scientific analysis of R&D projects,” said Shai Policker, CEO of MEDX Xelerator. “Her strong network in both Israel and the U.S. is a real asset for MEDX Xelerator, especially with the new influx of funding from the Israel Innovation Authority available for early stage medtech development.”
Landsburg will be responsible for deal flow generation and pipeline management, ongoing business development and marketing support for MEDX Xelerator’s portfolio companies and for the incubator itself. She will also focus on building and maintaining collaborations with relevant institutions and groups in Israel and abroad.
Landsberg formerly served as vice president of business development at Ramot, the tech transfer company of Tel Aviv University, commercializing its life science technologies and managing the life science pillar of the Momentum Fund. Prior to that, she was a business development manager at Dexcel Pharma, one of Israel’s largest globally operating pharma companies, where she pursued due-diligence of early-stage innovative pharma projects and performed scientific analysis of R&D projects for in-licensing and investment purposes. She was also co-founder and CEO at VitaPersonal Labs.
Landsberg has a strong academic background in bioinformatics including expertise in machine learning and artificial intelligence, earning a Ph.D. from Tel-Aviv University and a post-doctoral degree from Stanford University.
“MEDX Xelerator is a medtech incubator, committed to improving medical practice and solving complex clinical challenges by leveraging deep healthcare experience, industry-leading partners and an extensive network,” said Landsberg. “I am honored to join the MEDX Xelerator team and to help identify innovative early-stage medical startups that develop solutions to address true unmet clinical needs.”
“Inbal is a valuable and well-rounded addition to the MEDX Xelerator team given her strong background in fundraising, intellectual property know-how, as well as vast experience covering due diligence of investment opportunities and demonstrated ability to perform scientific analysis of R&D projects,” said Shai Policker, CEO of MEDX Xelerator. “Her strong network in both Israel and the U.S. is a real asset for MEDX Xelerator, especially with the new influx of funding from the Israel Innovation Authority available for early stage medtech development.”
Landsburg will be responsible for deal flow generation and pipeline management, ongoing business development and marketing support for MEDX Xelerator’s portfolio companies and for the incubator itself. She will also focus on building and maintaining collaborations with relevant institutions and groups in Israel and abroad.
Landsberg formerly served as vice president of business development at Ramot, the tech transfer company of Tel Aviv University, commercializing its life science technologies and managing the life science pillar of the Momentum Fund. Prior to that, she was a business development manager at Dexcel Pharma, one of Israel’s largest globally operating pharma companies, where she pursued due-diligence of early-stage innovative pharma projects and performed scientific analysis of R&D projects for in-licensing and investment purposes. She was also co-founder and CEO at VitaPersonal Labs.
Landsberg has a strong academic background in bioinformatics including expertise in machine learning and artificial intelligence, earning a Ph.D. from Tel-Aviv University and a post-doctoral degree from Stanford University.
“MEDX Xelerator is a medtech incubator, committed to improving medical practice and solving complex clinical challenges by leveraging deep healthcare experience, industry-leading partners and an extensive network,” said Landsberg. “I am honored to join the MEDX Xelerator team and to help identify innovative early-stage medical startups that develop solutions to address true unmet clinical needs.”